Evoq Remedies Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
- Paid Up Capital ₹ 24.90 Cr
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 67.42%
- Profit Growth 52.53%
- Ebitda 53.33%
- Net Worth 3017.87%
- Total Assets 314.24%
About Evoq Remedies
Evoq Remedies Limited (ERL) is a leading Public Limited Indian Non-Government Company incorporated in India on 24 February 2010 and has a history of 14 years and 11 months. Its registered office is in Ahmedabad, Gujarat, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 543500.
The Corporate was formerly known as Salus Life Science And Research Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 24.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Evoq Remedies Limited India is Yogesh Rajput as CFO. Bhumishth Patel, Narendrakumar Patel, Aesha Shah, and One other member serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
L24230GJ2010PLC059692
-
Company No.
059692
-
Stock Symbol
BSE : 543500
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
24 Feb 2010
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Listed
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Evoq Remedies?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Bhumishth Patel | Managing Director | 01-Aug-2024 | Current |
Yogesh Rajput | CFO | 12-Feb-2022 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Narendrakumar Patel | Director | 11-Sep-2023 | Current |
Aesha Shah | Additional Director | 01-Oct-2024 | Current |
Harsh Kothari | Director | 06-Sep-2024 | Current |
Financial Performance of Evoq Remedies.
Evoq Remedies Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 67.42% increase. The company also saw a substantial improvement in profitability, with a 52.53% increase in profit. The company's net worth Soared by an impressive increase of 3017.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Evoq Remedies?
In 2023, Evoq Remedies had a promoter holding of 73.53% and a public holding of 26.47%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Evoq Remedies?
Unlock and access historical data on people associated with Evoq Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evoq Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evoq Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.